141 related articles for article (PubMed ID: 14530256)
1. Influence of polymerase II processivity on alternative splicing depends on splice site strength.
Nogués G; Muñoz MJ; Kornblihtt AR
J Biol Chem; 2003 Dec; 278(52):52166-71. PubMed ID: 14530256
[TBL] [Abstract][Full Text] [Related]
2. Regulation of alternative splicing by a transcriptional enhancer through RNA pol II elongation.
Kadener S; Fededa JP; Rosbash M; Kornblihtt AR
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8185-90. PubMed ID: 12060763
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic effects of T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing.
Kadener S; Cramer P; Nogués G; Cazalla D; de la Mata M; Fededa JP; Werbajh SE; Srebrow A; Kornblihtt AR
EMBO J; 2001 Oct; 20(20):5759-68. PubMed ID: 11598018
[TBL] [Abstract][Full Text] [Related]
4. A slow RNA polymerase II affects alternative splicing in vivo.
de la Mata M; Alonso CR; Kadener S; Fededa JP; Blaustein M; Pelisch F; Cramer P; Bentley D; Kornblihtt AR
Mol Cell; 2003 Aug; 12(2):525-32. PubMed ID: 14536091
[TBL] [Abstract][Full Text] [Related]
5. RNA polymerase II C-terminal domain mediates regulation of alternative splicing by SRp20.
de la Mata M; Kornblihtt AR
Nat Struct Mol Biol; 2006 Nov; 13(11):973-80. PubMed ID: 17028590
[TBL] [Abstract][Full Text] [Related]
6. Muscle-specific exonic splicing silencer for exon exclusion in human ATP synthase gamma-subunit pre-mRNA.
Hayakawa M; Sakashita E; Ueno E; Tominaga S; Hamamoto T; Kagawa Y; Endo H
J Biol Chem; 2002 Mar; 277(9):6974-84. PubMed ID: 11744705
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional activators differ in their abilities to control alternative splicing.
Nogues G; Kadener S; Cramer P; Bentley D; Kornblihtt AR
J Biol Chem; 2002 Nov; 277(45):43110-4. PubMed ID: 12221105
[TBL] [Abstract][Full Text] [Related]
8. How slow RNA polymerase II elongation favors alternative exon skipping.
Dujardin G; Lafaille C; de la Mata M; Marasco LE; Muñoz MJ; Le Jossic-Corcos C; Corcos L; Kornblihtt AR
Mol Cell; 2014 May; 54(4):683-90. PubMed ID: 24793692
[TBL] [Abstract][Full Text] [Related]
9. Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer.
Cramer P; Cáceres JF; Cazalla D; Kadener S; Muro AF; Baralle FE; Kornblihtt AR
Mol Cell; 1999 Aug; 4(2):251-8. PubMed ID: 10488340
[TBL] [Abstract][Full Text] [Related]
10. Participation of the C-terminal domain of RNA polymerase II in exon definition during pre-mRNA splicing.
Zeng C; Berget SM
Mol Cell Biol; 2000 Nov; 20(21):8290-301. PubMed ID: 11027297
[TBL] [Abstract][Full Text] [Related]
11. Splicing of a myosin phosphatase targeting subunit 1 alternative exon is regulated by intronic cis-elements and a novel bipartite exonic enhancer/silencer element.
Dirksen WP; Mohamed SA; Fisher SA
J Biol Chem; 2003 Mar; 278(11):9722-32. PubMed ID: 12509424
[TBL] [Abstract][Full Text] [Related]
12. Pre-mRNA splicing is facilitated by an optimal RNA polymerase II elongation rate.
Fong N; Kim H; Zhou Y; Ji X; Qiu J; Saldi T; Diener K; Jones K; Fu XD; Bentley DL
Genes Dev; 2014 Dec; 28(23):2663-76. PubMed ID: 25452276
[TBL] [Abstract][Full Text] [Related]
13. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
[TBL] [Abstract][Full Text] [Related]
14. The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20.
Galiana-Arnoux D; Lejeune F; Gesnel MC; Stevenin J; Breathnach R; Del Gatto-Konczak F
J Biol Chem; 2003 Aug; 278(35):32943-53. PubMed ID: 12826680
[TBL] [Abstract][Full Text] [Related]
15. Promoter architecture modulates CFTR exon 9 skipping.
Pagani F; Stuani C; Zuccato E; Kornblihtt AR; Baralle FE
J Biol Chem; 2003 Jan; 278(3):1511-7. PubMed ID: 12421814
[TBL] [Abstract][Full Text] [Related]
16. Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells.
Shih SR; Krug RM
EMBO J; 1996 Oct; 15(19):5415-27. PubMed ID: 8895585
[TBL] [Abstract][Full Text] [Related]
17. An intron enhancer recognized by splicing factors activates polyadenylation.
Lou H; Gagel RF; Berget SM
Genes Dev; 1996 Jan; 10(2):208-19. PubMed ID: 8566754
[TBL] [Abstract][Full Text] [Related]
18. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
19. Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway.
Liu X; Mayeda A; Tao M; Zheng ZM
J Virol; 2003 Feb; 77(3):2105-15. PubMed ID: 12525645
[TBL] [Abstract][Full Text] [Related]
20. Splicing of phenylalanine hydroxylase (PAH) exon 11 is vulnerable: molecular pathology of mutations in PAH exon 11.
Heintz C; Dobrowolski SF; Andersen HS; Demirkol M; Blau N; Andresen BS
Mol Genet Metab; 2012 Aug; 106(4):403-11. PubMed ID: 22698810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
